This Trial is Conducted in Europe. The Aim of This Trial is to Investigate Pharmacokinetic (the Exposure of the Trial Drug in the Body) and Pharmacodynamic (the Effect of the Investigated Drug on the Body) Properties of Faster-acting Insulin Aspart in Subjects With Type 2 Diabetes Mellitus

Trial Profile

This Trial is Conducted in Europe. The Aim of This Trial is to Investigate Pharmacokinetic (the Exposure of the Trial Drug in the Body) and Pharmacodynamic (the Effect of the Investigated Drug on the Body) Properties of Faster-acting Insulin Aspart in Subjects With Type 2 Diabetes Mellitus

Recruiting
Phase of Trial: Phase I

Latest Information Update: 09 Nov 2017

At a glance

  • Drugs Insulin aspart (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Pharmacokinetics
  • Sponsors Novo Nordisk
  • Most Recent Events

    • 31 Oct 2017 Planned End Date changed from 14 Oct 2017 to 28 Feb 2018.
    • 31 Oct 2017 Planned primary completion date changed from 14 Oct 2017 to 28 Feb 2018.
    • 30 Jun 2017 Planned primary completion date changed from 14 Apr 2017 to 14 Oct 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top